Compare INCY & WSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INCY | WSM |
|---|---|---|
| Founded | 1991 | 1956 |
| Country | United States | United States |
| Employees | 2844 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7B | 26.2B |
| IPO Year | 1994 | 1995 |
| Metric | INCY | WSM |
|---|---|---|
| Price | $120.67 | $252.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 23 |
| Target Price | $130.63 | ★ $248.40 |
| AVG Volume (30 Days) | ★ 1.8M | 839.5K |
| Earning Date | 10-29-2026 | 11-18-2026 |
| Dividend Yield | N/A | ★ 1.17% |
| EPS Growth | ★ 4173.33 | 0.57 |
| EPS | 0.50 | ★ 4.77 |
| Revenue | $3,394,635,000.00 | ★ $7,806,816,000.00 |
| Revenue This Year | $18.06 | $6.18 |
| Revenue Next Year | $3.30 | $5.04 |
| P/E Ratio | $79.26 | ★ $54.51 |
| Revenue Growth | ★ 13.67 | 1.24 |
| 52 Week Low | $89.25 | $165.51 |
| 52 Week High | $132.60 | $261.11 |
| Indicator | INCY | WSM |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 56.91 |
| Support Level | $115.77 | $216.31 |
| Resistance Level | $130.53 | $258.00 |
| Average True Range (ATR) | 3.63 | 7.01 |
| MACD | 0.95 | 0.07 |
| Stochastic Oscillator | 79.39 | 55.72 |
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
With a retail and direct-to-consumer presence, Williams-Sonoma is a player in the nearly $300 billion domestic home category and $450 billion international home market, focused on expanding its exposure in the B2B ($80 billion total addressable market), marketplace, and franchise areas. Namesake Williams-Sonoma (153 stores) offers high-end cooking essentials, while Pottery Barn (181) provides casual home accessories. West Elm (117) is an emerging concept for young professionals, and Rejuvenation (13) offers lighting and house parts. Brand extensions include Pottery Barn Kids and Pottery Barn Teen (43) as well as Mark & Graham and GreenRow. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.